The therapeutic potential of inhibitors of the trypanothione cycle

Expert Opinion on Investigational Drugs

Volumn 11, Issue 2, 2002, Pages 217-231

  D'Silva, Claudius ^a   Daunes, Sylvie ^a  

^a MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

Author keywords

Chemotherapy; Glutathione; Inhibitors; Leishmaniasis; Protozoan diseases; Trypanosoma brucei brucei; Trypanosoma brucei rhodesiense; Trypanosoma cruzi; Trypanothione; Trypanothione reductase; Tryparedoxin

Indexed keywords

1,4 NAPHTHOQUINONE; ACRIDINE DERIVATIVE; ALLICIN; AMINOBIPHENYL DERIVATIVE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIPROTOZOAL AGENT; CLOMIPRAMINE; CRYSTAL VIOLET; EFLORNITHINE; ENZYME INHIBITOR; GLUTATHIONE DERIVATIVE; IMIPRAMINE; MEGLUMINE ANTIMONATE; MELARSOPROL; MENADIONE; MEPACRINE; N BENZOYLARGININE 2 NAPHTHYLAMIDE; NATURAL PRODUCT; NIFURTIMOX; PEPTIDE DERIVATIVE; PHENOTHIAZINE DERIVATIVE; PLUMBAGIN; POLYAMINE DERIVATIVE; PROMAZINE; QUINONE DERIVATIVE; STIBOGLUCONATE SODIUM; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPANOTHIONE REDUCTASE INHIBITOR; TRYPAREDOXIN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTITRYPANOSOMAL AGENT; DRUG DERIVATIVE; GLUTATHIONE; GLUTATHIONE RECEPTOR; OXIDOREDUCTASE; RECEPTOR; SPERMIDINE; THIOREDOXIN; TRYPANOTHIONE; TRYPANOTHIONE REDUCTASE; TRYPAREDOXIN;

AFRICAN TRYPANOSOMIASIS; ANEMIA; ANTIPROTOZOAL ACTIVITY; CHAGAS DISEASE; CONTROLLED STUDY; DRUG BINDING; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG TARGETING; HUMAN; IN VITRO STUDY; LEISHMANIASIS; LEUKOPENIA; REVIEW; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; STRUCTURE ACTIVITY RELATION;

ANIMALS; CHAGAS DISEASE; ENZYME INHIBITORS; GLUTATHIONE; HUMANS; LEISHMANIASIS; NADH, NADPH OXIDOREDUCTASES; RECEPTORS, PEPTIDE; SPERMIDINE; STRUCTURE-ACTIVITY RELATIONSHIP; THIOREDOXIN; TRYPANOCIDAL AGENTS; TRYPANOSOMIASIS, AFRICAN;

EID: 0036166378     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.2.217     Document Type: Review

References (113)

1. Trypanosomiasis and leishmaniasis. Between the idea and the reality of control
2. The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes
3. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala
4. Resistance to DL-α-difluoromethylornithine by clinical isolates of Trypanosoma brucei rhodesiense. Role of S-adenosylmethionine
5. Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to DL-α-difluoromethylornithine
6. The treatment of human African trypanosomiasis
7. Metabolism and functions of trypanothione in the kinetoplastida
8. The challenge of Chagas' disease chemotherapy: An update of drugs assayed against Trypanosoma cruzi
9. Differential effect of Amphotericin B on the three evolutive stages of Trypanosoma cruzi and on the host cell-parasitic interaction
10. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: A multi-centre trial
11. Chemotherapy of human leishmaniasis and trypanosomiasis
12. Amphotericin B: New life for an old drug
13. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major-a double-blind study
14. Practical progress and new drugs for changing patterns of leishmaniasis
15. Trypanothione lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress
16. Sleeping sickness: Irreversible inhibitors of S-adenosylmethionine decarboxylase as antitrypanosomal agents
17. Prospects for antiparasitic drugs
18. A structure-based approach to drug discovery; crystallography and implications for the development of antiparasitic drugs
19. Validating targets for antiparasitic chemotherapy
20. Heteroatom-substituted fatty acid analogs as substrates for N-myristoyltransferase: An approach for studying both enzymology and function of protein acylation
21. An analog of myristic acid with selective toxicity for African trypanosomes
22. Ribonucleotide reductase: A new target for antiparasite therapies
23. Identification and biosynthesis of N1,N9-bis(glutathionyl) aminopropylcadaverine (homotrypanothione) in Trypanosoma cruzi
24. Enzymes of parasite thiol metabolism as drug targets
25. Biochemical characterization of a trypanosome enzyme with glutathione-dependent peroxidase activity
26. Anti-sleeping sickness drugs and cancer chemotheraphy
27. Disulphide-reductase inhibitors as chemotherapeutic agents: The design of drugs of trypanosomiasis and malaria
28. Rational drug design using trypanothione reductase as a target for anti-trypanosomal and anti-leishmanial drug leads
29. Purification and Characterization of Trypanothione Reductase from Crithidia fasciculata, a newly discovered member of the family of disulphide-containing flavoprotein reductases
30. NATO ASI Senes: Host-parasite cellular and molecular interactions in protozoal infections
31. Substrate specificity of the flavoprotein trypanothione disulfide reductase from Crithidia fasciculata
32. Molecular characterization of the trypanothione reductase gene from Crithidia fasciculata and Trypanosoma brucei: Comparison with other flavoprotein disulfide oxidoreductases with respect to substrate mechanism
33. Cloning, sequencing and demonstration of polymorphism in trypanothione reductase from Crithidia fasciculata
34. Trypanothione reductase from Trypanosoma cruzi. Purification and characterization of the crystalline enzyme
35. Characterization of melarsen-resistant Trypanosoma.brucei brucei with respect to cross resistance to other drugs and trypanothione metabolism
36. Trypanothione reductase of Trypanosoma Congolense: Gene isolation, primary sequence determination, and comparison to glutathione reductase
37. Expression of Trypanosoma congolense trypanothione reductase in Eschericha coli: Overproduction, purification and characterisation
38. Cloning, sequencing, overproduction and purification of trypanothione reductase from Trypanosoma Cruzi
39. NADPH-dependent disulphide reductases
40. Lipoamide dehydrogenase, glutathione reductase, thioredoxin reductase, and mercuric ion reductase- A family of flavoenzyme transhydrogenases
41. Crystal structure of Trypanosoma cruzi trypanothione reductase in complex with trypanothione, and the structure-based discovery of new natural product inhibitors
42. 1-glutathionylspermidine disulphide at 0.28-nm resolution
43. Crystal structure of the Trypanosoma cruzi trypanothione reductase mepacrine complex
44. Synthesis of N-benzyloxycarbonyl-L-cysteinylglycine 3-dimethylaminopropylamide disulphide: A cheap and convenient new assay for trypanothione reductase
45. Rational design of peptide-based inhibitors of trypanothione reductase as potential antitrypanosomal drugs
46. Rationally designed selective inhibitors of trypanothione reductase
47. Rational drug design using trypanothione reductase as a target for anti-trypanosomal and anti-leishmanial drug leads
48. Synthesis of non reducible inhibitors for trypanothione reductase from Trypanosoma cruzi
49. Inhibition of trypanothione reductase by substrate analogues
50. Bimane cyclic esters, possible stereologues of trypanothione as antitrypanosomal agents. Bimanes 29
51. Kukoamine A and other hydrophobic acylpolyamines: Potent And selective inhibitors of Crithidia fasciculata trypanothione reductase
52. Novel Polyamine derivatives as potent competitive inhibitors of Trypanosoma cruzi trypanothione reductase
53. Polyamines with N-(3-phenylpropyl) substituents are effective competitive inhibitors of trypanothione reductase and trypanocidal agents
54. Polyamine derivatives as inhibitors of trypanothione reductase and assessment of their trypanocidal Activities
55. Comparison of resin and solution screening methodologies in combinatorial chemistry and the identification of a 100 nM inhibitor of trypanothione reductase
56. Rationally designed selective inhibitors of trypanothione reductase. Phenothiazines and related tricyclics as lead structures
57. Inhibition of Trypanosoma cruzi trypanothione reductase by crystal violet
58. Antiprotozoal and cytotoxicity evaluation of sulfonamide and urea analogues of quinacrine
59. Phenothiazines inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs
60. Inhibition of Trypanosoma cruzi trypanothione reductase by acridines: Kinetic studies and structure-activity relationships
61. Rationally design of selective ligands for trypanothione reductase from Trypanothione cruzi. Structurally effects on the inhibition by dibenzazepines based on impipramine
62. Use of an additional hydrophobic binding site, the Z site, in the rational drug design of a new class of stronger trypanothione reductase inhibitor, quaternary alkylammonium phenothiazines
63. Interaction of aza analogs of chloropromazine with the dopamine A2 receptor
64. 1-glutathionylspermidine diulphide at 0.28-nm resolution
65. 2-Amino diphenyldisulphides as new inhibitors of trypanothione reductase
66. 2-Aminodiphenylsulfides as inhibitors of trypanothione reductase modification of the side chain
67. New potent inhibitors of trypanothione reductase from Trypanosoma cruzi in the 2-aminodiphenylsulfide series
68. The mode of association of amphiphilic drugs in aqueous solution
69. Potent and specific inhibitors of trypanothione reductase from Trypanosoma cruzi: Bis(2-aminodiphenylsulfides) for fluorescent labeling studies
70. Mechanism of reduction of quinines by Trypanosoma congolense trypanothione reductase
71. Subversive substrates for the enzyme trypanothione disulphide reductase: Alternative approach to chemotherapy of Chagas disease
72. Trypanothione reductase from Trypanosoma cruzi. Catalytic properties of the enzyme and inhibition studies with trypanocidal compounds
73. 2- and 3-Substituted 1,4-Naphthoquinone derivatives as subversive substrates of trypanothione reductase and lipoamide dehydrogenase from Trypanosoma cruzi: Synthesis and correlation between redox cycling cytotoxicity
74. The organosulfur chemistry of the genus allium. Implications for the organic chemistry of sulfur
75. Inhibition of phosphatidylcholine biosynthesis and cell proliferation in Trypanosoma cruzi by Ajoene an antiplatelet compound isolated from garlic
76. Ajoene is an inhibitor and subversive substrate of human glutathione reductase: Crystallographic, kinetic, and spectroscopic studies
77. (2,2′:6′,2″-Teryridine)platinum(II) complexes are irreversible inhibitors of Trypanosoma cruzi trypanothione reductase but not of human glutathione reductase
78. Sequence analysis of the tryparedoxin peroxidase gene from Crithidia fasciculata and its functional expression in Escherichia coli
79. A unique cascade of oxidoreductases catalyses trypanothione-dependent peroxide metabolism in Crithidia fasciculata
80. Catalytic characteristics of tryparedoxin
81. Cloning, expression and reconstitution of the trypanothione-dependent peroxidase system of Crithidia fasciculata
82. Trypanosoma brucei tryparedoxin, a thioredoxin-like protein in African trypanosomes
83. Thioredoxin
84. Thioredoxin and glutaredoxin systems
85. Thioredoxins: Universal, yet specific thiol disulfide redox cofactors
86. Sequence heterologous expression and functional characterisation of a novel tryparedoxin from Crithidia fasciculata
87. Identification and functional characterization of thioredoxin from Trypanosoma brucei brucei
88. Cytoplasmic localization of the trypanothione peroxidase system in Crithidia fasciculata
89. Subcellular distribution of trypanothione reductase in blood-stream and procyclic forms of Trypanosoma brucei
90. Trypanosoma cruzi immunolocalization of trypanothione reductase
91. Distinct mitochondrial and cytosolic enzymes mediate trypanothione-dependent peroxide metabolism in Trypanosoma cruzi
92. Molecular characterisation of mitochondrial and cytosolic trypanothione-dependent tryparedoxin peroxidases in Trypanosoma brucei
93. The high resolution crystal structure of recombinant Crithidia fasciculata tryparedoxin-I
94. Structures of tryparedoxins revealing interaction with trypanothione
95. Photoaffinity labels for enzymes capable of binding glutathione of its disulphide
96. Photoaffinity labels for glutathione and glutathione disulphide-utilizing systems
97. Glutathione derivatives as inhibitors of glutaredoxin and ribonucleotide reductase from Escherichia coli
98. Reinvestigation of the roles of the carboxyl groups of glutathione with yeast glyoxalase I
99. Inhibition and recognition studies on the glutathione-binding site of equine liver glutathione S-transferase
100. Photoaffinity labelling of glutaredoxin from Escherischia coli
101. Photoaffinity labelling of yeast glutathione reductase by a bifunctional aryl azide derivative of oxidised glutathione
102. Role of the N-terminus of glutathione in the action of yeast glyoxalase I
103. Structure-activity study on the in vitro antiprotozoal activity of glutathione derivatives
104. Interaction of a glutathione S-conjugate with glutathione reductase: Kinetic and x-ray crystallographic studies
105. s to the in vitro antiprotozoal activity of glutathione derivatives
106. Glutathione derivatives active against T.b.rhodesience & T.b.brucei in vitro
107. The mode of action of glutathione derivatives as antiprotozoal agents active against trypanosomes
108. Receptor based biosensors
109. A concanavilin a coated piezoelectric crystal biosensor
110. Enzyme-linked immunosorbent assay for ceftazidime in airborne samples
111. Mechanism-based competitive inhibitors of glyoxalase I: Intracellular delivery, in vitro antitumor activities, and stabilities in human serum and mouse serum